Insider buying last 90 days
No open-market insider purchases were filed for DFTX in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every DFTX insider filing, plotted on the chart in Gekko.Open DFTX in Gekko
NASDAQ: DFTX
Definium Therapeutics (DFTX) Stock Analysis & Forecast
Sep 28 close
$38.41+2.24 (+6.2%)
Gekko Brief
AI summaryDefinium Therapeutics moves this week on positive Phase III results for DT120, showing statistically significant improvements in generalized anxiety disorder and major depressive disorder after a single treatment. The company also announced new employee inducement grants, and several officers filed to sell shares tied to restricted stock vesting, though the clinical data remains the more central development. Analyst commentary during the week pointed to price target forecasts ranging between $66 and $91.
DFTX closed at $38.41, up 6.2%, with the stock sitting between its 50-day average of $41.60 and 200-day average of $26.90, reflecting a mixed trend. The GekkoIndex reads 60.8, placing the stock in the Accumulation zone. Price sits 21.8% below Gekko Fair Value of $49.11. Over the past year the stock has returned 293.1%, though the most recent month shows a decline of 12.3%.
Earnings are scheduled for 5 November, 37 days out and beyond a typical 20-trading-day hold, with the last report showing an actual EPS of -1.44 against an estimate of -0.54 and a 3.9% reaction. In the last 30 days there have been 2 unusual options signals, with call premium of $428,865 against put premium of $258,000. Seasonality over 5 years shows an average 20-day return of -6.1% from this point, rising in 2 of those years. Analyst coverage stands at 15 firms, all rated buy, with a consensus target of $71.65.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Definium Therapeutics price vs fair value
Close $38.41200-day averageGekko Fair Value $49.11
Definium Therapeutics quick facts
- Market cap
- $5.10B
- P/E ratio
- —
- Forward P/E
- —
- EPS, TTM
- −$3.43
- Revenue, TTM
- $0
- Profit margin
- 0%
- Dividend yield
- —
- Beta
- 2.24
- Volume
- 2.99M avg 2.38M
- 1-year return
- +293.1%
- Typical daily move
- ±5.6%
- Typical 20-day move
- ±13.2%
- 50-day average
- $41.60
- 200-day average
- $26.90
- Next earnings
- Nov 5 after close
- Shares outstanding
- 134.4M
Definium Therapeutics swing-trade checklist
Definium Therapeutics scores 4 supportive, 1 mixed and 1 headwind across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed1 headwind
- Trendmixed
Averages disagree
Close $38.41 sits between the 50-day ($41.60) and 200-day ($26.90) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
60.8, Accumulation
Reading 60.8 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
21.8% below
Price is 21.8% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneysupportive
Leans bullish
Last 30 days: 2 unusual options signals.
See smart money - Earnings risksupportive
Reports in 37 days
Next report Nov 5, 2026, 37 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalityheadwind
−6.1% on average
From this point in the calendar, the next 20 trading days averaged −6.1% over 5 years, rising in 2 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Definium Therapeutics stock chart and price history
Definium Therapeutics closed at $38.41 on Sep 28, 2026, +293.1% over the past year, inside a 52-week range of $9.62 to $49.70.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −12.3%
- 3 months
- −17.5%
- 6 months
- +114.8%
- 1 year
- +293.1%
The full DFTX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open DFTX in Gekko
Follow Definium Therapeutics through every session
Put DFTX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track DFTX in GekkoFree for 7 days. No credit card required.
About Definium Therapeutics
Definium Therapeutics is a clinical-stage biopharmaceutical company focused on treatments for brain health and neurological conditions. Its work centers on experimental drug candidates rather than approved products, with the aim of addressing disorders that affect cognition and behavior. The company is best known for its pipeline of compounds still under clinical investigation rather than any commercialized therapy.
Among its lead programs is MM120, now in Phase 3 trials for generalized anxiety disorder and attention deficit hyperactivity disorder. It is also advancing MM402, an R-enantiomer of MDMA, through Phase 1 testing aimed at the core symptoms of autism spectrum disorder. These programs suggest a business built around drug development milestones rather than steady product sales, with progress tied to clinical trial outcomes.
Definium Therapeutics is headquartered in New York, New York. Its shares trade on the NASDAQ under the ticker DFTX.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- definiumtx.com
Definium Therapeutics GekkoIndex: the smart money zone
Definium Therapeutics’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 60.8, in the Accumulation zone, down 1.7 points over five sessions.
60.8Accumulation
Down 1.7 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days |
|---|---|---|---|
| Buying | 40 | +1.6% | +12.1% |
| Accumulation (current zone) | 157 | +1.8% | +6.4% |
| Neutral | 392 | +2.3% | +9.7% |
| Distribution | 64 | +4.9% | +17.6% |
| Selling | 19 | 0.0% | +6.1% |
Average DFTX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the DFTX price, zone by zone.Track DFTX in Gekko
Is Definium Therapeutics stock overvalued? Gekko Fair Value
Definium Therapeutics trades 21.8% below Gekko Fair Value of $49.11, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Definium Therapeutics shares are worth, recalculated every trading day.
$49.11
Gekko Fair Value, Sep 29, 2026
21.8% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open DFTX in Gekko
Definium Therapeutics insider and Congress trading
No open-market insider purchases were filed for Definium Therapeutics, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in DFTX were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for DFTX, plotted on the chart in Gekko.Open DFTX in Gekko
Buybacks
Definium Therapeutics has been buying back its own shares.
- Bought back, quarter ended Mar 31, 2022
- $407K
- As a share of market cap
- 0.01%
From company filings.
Unusual options activity last 30 days
2signals, 62% of the flagged premium in calls.
Latest: Bearish flow on Sep 15, $275K in unusual premium.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds DFTX.
0added1opened0trimmed0sold out
Every signal with its contract, strike and premium, and which funds are on each side.Unlock in Gekko
Definium Therapeutics earnings: next date and track record
Definium Therapeutics reports on Nov 5, 2026, after the close (37 days away), and beat the EPS estimate in 2 of its last 8 reports.
Next earnings report
Nov 5, 2026
Expected after the close, 37 days away
- EPS estimate
- −$0.54
2 of 8reports beat the EPS estimate
±7.3%average move across the report
4 of 8reports followed by a gain
Share-price move across each report
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 6, 2026 | −$1.44 est −$0.54 | — | +3.9% |
| May 7, 2026 | −$0.71 est −$0.48 | — | −5.8% |
| Feb 26, 2026 | −$0.45 est −$0.45 | — | −1.0% |
| Nov 6, 2025 | −$0.78 est −$0.52 | — | +1.5% |
| Jul 31, 2025 | −$0.50 est −$0.38 | — | −6.5% |
| May 8, 2025 | −$0.35 est −$0.36 | — | −6.7% |
| Mar 6, 2025 | −$0.41 est −$0.31 | — | +7.1% |
| Nov 7, 2024 | −$0.18 est −$0.28 | — | +25.8% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Definium Therapeutics stock forecast and analyst price targets
Analysts’ average 12-month price target for Definium Therapeutics is $71.65, +86.5% from the last close, from 15 firms rating the stock in the last 90 days.
$71.65consensus 12-month target, +86.5% from the last close
Now $38.41Avg $71.65
Low $53High $91
Each firm’s latest rating in the last 90 days: 15 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 19 | LifeSci Capital | $78 | +103.1% |
| Sep 15 | Robert W. Baird | $79 | +105.7% |
| Sep 15 | Maxim Group | $55 | +43.2% |
| Sep 15 | Stifel Nicolaus | $67 | +74.4% |
| Sep 15 | JonesTrading | $90 | +134.3% |
+6.4%average 20-day move after past Accumulation readings
−6.1%average move over the next 20 trading days in the last 5 years
±5.6%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Definium Therapeutics seasonality: the next 20 trading days
Over the next 20 trading days from Sep 29, Definium Therapeutics averaged −6.1% across the last 5 years, rising in 2 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | −2.9% | 1 of 5 |
| Next 10 trading days | −7.3% | 1 of 5 |
| Next 15 trading days | −2.1% | 3 of 5 |
| Next 20 trading days | −6.1% | 2 of 5 |
| Next 30 trading days | −0.7% | 1 of 5 |
For scale, DFTX’s typical 20-trading-day move in either direction is about 13.2%.
Definium Therapeutics market cap and key statistics
Definium Therapeutics’s market cap is $5.10B and revenue of $0 over the last twelve months.
Valuation
- Market cap
- $5.10B
- EPS, TTM
- −$3.43
- Gekko Fair Value
- $49.11
Trading
- Volume
- 2.99M
- Avg volume, 20 days
- 2.38M
- 52-week high
- $49.70
- 52-week low
- $9.62
- Shares outstanding
- 134.4M
Financials
- Revenue, TTM
- $0
- Profit margin
- 0%
- Return on equity
- -64.1%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 2.24
- Typical daily move
- ±5.6%
- Typical 20-day move
- ±13.2%
Definium Therapeutics stock news this week
Coverage of Definium Therapeutics this week reads neutral: 3 positive, 6 neutral and 1 negative headlines.
- Definium Therapeutics Announces New Employee Inducement GrantsBusiness Wire, Sep 28
- Form 4 Definium Therapeutics Inc For: 27 September By Investing.comInvesting.com Nigeria, Sep 28
- An officer sold 2,867 shares in the prior three months and lists 3,097 for sale at Definium Therapeutics (DFTX).Stock Titan, Sep 26
- Form 144 DEFINIUM THERAPEUTICS For: 25 September By Investing.comInvesting.com UK, Sep 26
- After selling 13,008 shares in June, Definium Therapeutics (DFTX) officer Mark Sullivan proposes to sell 14,051.Stock Titan, Sep 26
- Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and DepressionTradingView, Sep 24
Definium Therapeutics peers
Definium Therapeutics’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 17.9% above |
| JNJJohnson & Johnson | Neutral | 0.5% above |
| ABBVAbbVie | Neutral | 23.3% above |
| MRKMerck | Neutral | 4.2% below |
| AZNAstraZeneca | Neutral | 39.9% below |
| PFEPfizer | Neutral | 4.0% below |
A peer links to its own page where one exists.
Definium Therapeutics stock FAQ
What is Definium Therapeutics’s market cap?
Definium Therapeutics’s market cap is $5.10B at the Sep 28, 2026 close of $38.41, with 134.4M shares outstanding.
What is the Definium Therapeutics stock forecast?
The consensus analyst 12-month price target for Definium Therapeutics is $71.65, +86.5% from the last close. Of the 15 firms that rated the stock in the last 90 days, 15 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Definium Therapeutics stock overvalued or undervalued?
On Gekko’s estimate Definium Therapeutics is undervalued: the Sep 28, 2026 close of $38.41 is 21.8% below Gekko Fair Value of $49.11. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Definium Therapeutics report earnings next?
Definium Therapeutics is expected to report on Nov 5, 2026, after the market closes (37 days away). Analysts expect earnings of −$0.54 per share. Definium Therapeutics beat the earnings estimate in 2 of its last 8 reports, moving 7.3% on average across the report.
What is Definium Therapeutics’s 52-week high and low?
Definium Therapeutics’s 52-week high is $49.70 and its 52-week low is $9.62; it closed at $38.41 on Sep 28, 2026, +293.1% over the past year.
Is Definium Therapeutics stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 6 items with data read as supportive (gekkoindex, fair value, smart money and earnings risk), 1 as mixed (trend) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.
Is there unusual options activity in Definium Therapeutics?
Gekko flagged 2 unusual options signals in Definium Therapeutics over the last 30 days, with $429K of flagged premium in calls and $258K in puts. The latest, bearish flow, was on Sep 15, 2026 with $275K in unusual premium. The signal-by-signal table is in Gekko.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Definium Therapeutics the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.